2021
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal Of Clinical Oncology 2021, 39: 2375-2385. PMID: 34077270, DOI: 10.1200/jco.20.03398.Peer-Reviewed Original ResearchConceptsInvasive disease-free survivalT-DM1Breast cancerStage IStage I HER2-positive breast cancerHER2-positive breast cancerHuman epidermal growth factor receptorAdjuvant T-DM1Co-primary objectivesDisease-free survivalPatient-reported outcomesEpidermal growth factor receptorGrowth factor receptorProtocol therapyAnalysis populationTrastuzumab emtansineClinical trialsRelevant toxicityPatientsFactor receptorLess toxicityWeeksTrastuzumabCancerPaclitaxel
2014
Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).
Carey L, Barry W, Pitcher B, Hoadley K, Cheang M, Anders C, Henry N, Tolaney S, Dang C, Krop I, Harris L, Berry D, Perou C, Winer E, Hudis C. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). Journal Of Clinical Oncology 2014, 32: 506-506. DOI: 10.1200/jco.2014.32.15_suppl.506.Peer-Reviewed Original Research
2010
Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer.
Sikov W, Perou C, Golshan M, Collyar D, Berry D, Hahn O, Singh B, Hudis C, Winer E. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. Journal Of Clinical Oncology 2010, 28: tps110-tps110. DOI: 10.1200/jco.2010.28.15_suppl.tps110.Peer-Reviewed Original ResearchLetters: Andrew Seidman, Clifford Hudis, and Eric Winer on the Point-Counterpoint on Dosing for Paclitaxel for Ovarian Cancer (11/25/09 issue); Letters: Simone's OncOpinion: 'Professional Professional Careers for ‘Old’ Guys (12/10/09 issue), by Leonard Zwelling MD; Letters: “Advances in Bone Biology Research Setting Stage for New Cancer Therapies” (11/25/09 issue), by W. Reid Pitts, Jr., MD
Seidman A, Hudis C, Winer E, Zwelling L. Letters: Andrew Seidman, Clifford Hudis, and Eric Winer on the Point-Counterpoint on Dosing for Paclitaxel for Ovarian Cancer (11/25/09 issue); Letters: Simone's OncOpinion: 'Professional Professional Careers for ‘Old’ Guys (12/10/09 issue), by Leonard Zwelling MD; Letters: “Advances in Bone Biology Research Setting Stage for New Cancer Therapies” (11/25/09 issue), by W. Reid Pitts, Jr., MD. Oncology Times 2010, 32: 3-4. DOI: 10.1097/01.cot.0000368015.24121.d3.Peer-Reviewed Original Research
2009
5034 Troponin I and C-reactive protein as biomarkers for changes in left ventricular ejection fraction in patients with early stage breast cancer treated with dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib
Morris P, Chen C, Lin N, Moy B, Come S, Abbruzzi A, Winer E, Norton L, Hudis C, Dang C. 5034 Troponin I and C-reactive protein as biomarkers for changes in left ventricular ejection fraction in patients with early stage breast cancer treated with dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib. European Journal Of Cancer Supplements 2009, 7: 271. DOI: 10.1016/s1359-6349(09)70926-7.Peer-Reviewed Original Research
2008
Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)
Dang C, Lin N, Lake D, Dickler M, Modi S, Seidman A, Steingart R, Norton L, Winer E, Hudis C. Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA). Journal Of Clinical Oncology 2008, 26: 518-518. DOI: 10.1200/jco.2008.26.15_suppl.518.Peer-Reviewed Original Research
2007
Dose-dense nab-paclitaxel (nanoparticle albumin-bound paclitaxel) in adjuvant chemotherapy for breast cancer: A feasibility study
Burstein H, Mayer E, Peppercorn J, Parker L, Hannagan K, Moy B, Younger J, Schapira L, Wulf G, Gelman R, Winer E. Dose-dense nab-paclitaxel (nanoparticle albumin-bound paclitaxel) in adjuvant chemotherapy for breast cancer: A feasibility study. Journal Of Clinical Oncology 2007, 25: 594-594. DOI: 10.1200/jco.2007.25.18_suppl.594.Peer-Reviewed Original ResearchG-CSF supportNab-paclitaxelFebrile neutropeniaTreatment delayBreast cancerDoxorubicin/cyclophosphamideNab-paclitaxel therapyQuality of lifeDose-denseAdjuvant chemotherapyEligible patientsNeoadjuvant chemotherapyTaxane chemotherapyDose reductionFull cohortStage IPatientsNeutropeniaChemotherapyInstitutional studyPaclitaxelSignificant financial relationshipCycle 6CancerPrior studies
2006
P-166 Chemotherapy-related amenorrhea in premenopausal women with breast cancer: The effect of paclitaxel, dose density and trastuzumab
Abusief M, Missmer S, Ginsburg E, Weeks J, Winer E, Partridge A. P-166 Chemotherapy-related amenorrhea in premenopausal women with breast cancer: The effect of paclitaxel, dose density and trastuzumab. Fertility And Sterility 2006, 86: s194. DOI: 10.1016/j.fertnstert.2006.07.514.Peer-Reviewed Original Research
2005
Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG
Citron M, Berry D, Cirrincione C, Livingston R, Gradishar W, Perez E, Muss H, Norton L, Winer E, Hudis C. Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG. Journal Of Clinical Oncology 2005, 23: 620-620. DOI: 10.1200/jco.2005.23.16_suppl.620.Peer-Reviewed Original Research